Danish and English researchers have completed a phase one study, which is a study on healthy people, Science Radio first reportedGeneral Chat Chat Lounge Bjorn Hermann, associate professor of clinical microbiology, conducts research on chlamydia at the Uppsala Academic Hospital Spital and says that study is important because it is the first stage of the vaccine for chlamydia.
– By the way, it's a breakthrough, he tells SVT News.
He states that there are still many years until the vaccine is released in the market, but this vaccine candidate's study has shown two things:
– Partly because it has no harmful side effects, it is important to move on. Another important thing is that the immune system is started in such a way that one can expect protection against Chlamydia infection, says Bjorn Herman.
There are 130 million infections a year
Chlamydia is the most common sexually transmitted disease in the world. According to the World Health Organization, every year, some 60 million people worldwide are infected and 000,000 of them are Swedish.
Chlamydia can be treated with antibiotics, but infection is not always the cause of the symptoms, so it is difficult to prevent the spread of the infection. Infection can lead to serious complications, especially for women who suffer from fallopian tubes, ectopic pregnancy, and infertility.
– These are important reasons for vaccination, says Bern Herrmann.